BioNTech to Present First Global Data for Pumitamig/Elfetabart Drozuntecan Combination at WCLC 2026
BNTX sits 40% above its 52-week low of $79.52 on elevated volume (8.2× avg).
Summary
BioNTech announced it will present new clinical data at WCLC 2026 in September, including first global data for the pumitamig/elfetabart drozuntecan combination and updated overall survival for gotistobart.
Key Events · Product Development and Regulatory · BNTX
-
First Global Data for Novel-Novel Combination
At WCLC 2026, BioNTech will present first data from the Phase 1/2 trial of pumitamig plus elfetabart drozuntecan in advanced/metastatic SCLC and NSCLC. This is the first combination data for any PD-(L)1xVEGF bispecific with an ADC in lung cancer.
-
Updated Overall Survival for Gotistobart
Updated overall survival data from stage 1 of the PRESERVE-003 Phase 3 trial of gotistobart in 2L+ squamous NSCLC will be presented, adding to evidence for a chemotherapy-free approach.
-
Broad Lung Cancer Pipeline
BioNTech is advancing 16 ongoing lung cancer trials, including five Phase 3 trials and two novel-novel combination trials, across subtypes and treatment settings.
-
Presentation Dates at WCLC 2026
Data will be presented September 12-15, 2026 in Seoul, with the pumitamig/elfetabart drozuntecan oral presentation on September 15 and gotistobart mini oral on September 14.
Analysis · BNTX · Life Sciences
At WCLC 2026, BioNTech will present first-in-class data for its pumitamig plus elfetabart drozuntecan combination in lung cancer, along with updated overall survival data for gotistobart. This marks the first global data for a PD-(L)1xVEGF bispecific combined with an ADC in lung cancer, a key differentiator for BioNTech's oncology pipeline. The data could validate the novel-novel combination strategy and inform registrational paths for pumitamig, a core asset.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 29.3% of the 1512 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BNTX was trading at $111.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.4B. The 52-week trading range was $79.52 to $124.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.